KOSDAQBiotech & Pharma054670

Daehan Nupharm

₩4,820▲ 0.10%2026-11-18 close
Market Cap
₩69.2B
Turnover
₩72,207,005
Volume
10K
Shares out.
14.4M
PER
4.4×
PBR
0.5×
EPS
₩1,146
Dividend Yield
1.98%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

Plant Transition Puts Margin Recovery to the Test

Daehan Nupharm swung to an operating loss of KRW 3.06 billion in the third quarter of 2026 as new-plant fixed costs and R&D spending rose, and its injectable line, targeted for early 2027, becomes the test for margin recovery.

  1. 1

    Sales have stayed near KRW 200 billion, moving from KRW 198 billion in 2022 to KRW 202.4 billion in 2025.

  2. 2

    The operating margin fell from 13.9% in 2022 to 5.8% in 2025, when operating profit was KRW 11.7 billion, down 37.2% year on year.

  3. 3

    The third quarter of 2026 recorded an operating loss of KRW 3.06 billion, and company-announced R&D spending for the first nine months rose 24.8% to KRW 7.9 billion.

  4. 4

    The new plant was reported at a total investment of about KRW 81 billion, and its injectable line is targeted to start in early 2027 while qualification review is under way, as reported in May 2026.

  5. 5

    The debt ratio stood at 93.8% at the end of 2025, and the company said the debt ratio for the first nine months of 2026 fell to 87.8%, down year on year.

02

Business structure

Daehan Nupharm was founded in 1984 and listed on KOSDAQ in 2002. It is a mid-sized pharmaceutical company focused on manufacturing and selling human and veterinary medicines.

Its prescription drug business centers on metabolic diseases and peptic ulcer treatments, and it is extending its pipeline into obesity drug R&D and dementia and Parkinson's disease.

Key products include Rapiduo, a treatment for reflux esophagitis launched in 2023, and DH Pujol, a fluconazole formulation for dogs launched in 2024. Product sales as a share of total sales rose from 68.18% in 2022 to 70.80% in 2023 and 76.05% in 2024.

In injectables, the company is adding wellness injection items and improved-formulation new drugs to strengthen its portfolio. Its pet brand DAHNGJU and health functional food brand DNEW diversify the business.

Production runs the new plant alongside the existing plant to secure manufacturing capacity that meets global standards.

The new plant, reported in 2025, includes an injectable line reflecting EU GMP Annex 1 guidelines and a solid dosage line with a BIN system, with reported annual capacity of 800 million tablets and 200 million capsules. The largest shareholder is Chairman Lee Wan-jin, who held 26.53% as reported in 2025.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩48.9B₩2.1B4.3%
2025Q4₩51.8B₩2.3B4.5%
2026Q1₩54.8B₩3.1B5.7%
2026Q2₩56B₩2.2B3.8%
2026Q3₩49.6B-₩3.1B−6.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩198B₩27.6B₩24.3B13.9%23.6%64.5%
2023₩204.2B₩18.8B₩12.5B9.2%11.5%61.8%
2024₩202.2B₩18.7B₩15.5B9.2%12.3%76.4%
2025₩202.4B₩11.7B₩15.3B5.8%10.9%93.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual sales were KRW 198 billion in 2022, KRW 204.2 billion in 2023, KRW 202.2 billion in 2024 and KRW 202.4 billion in 2025, and 2023 was the largest year in the 2022 to 2025 period.

Operating profit went from KRW 27.6 billion in 2022 to KRW 18.8 billion in 2023 (down 31.8% year on year), KRW 18.7 billion in 2024 (down 0.8%) and KRW 11.7 billion in 2025 (down 37.2%), a three-year decline running from 2023 through 2025. The operating margin moved from 13.9% to 9.2%, 9.2% and 5.8%.

Selling and administrative expenses rose from KRW 63 billion in 2022 to KRW 75.2 billion in 2023 and KRW 78.2 billion in 2024, so cost pressure weighed on margins while sales stayed flat.

Profit attributable to owners of the parent fell from KRW 24.3 billion in 2022 to KRW 12.5 billion in 2023 (down 48.4%), and the company attributed the 2023 decline partly to about KRW 7.1 billion in tax assessments paid that year.

It recovered to KRW 15.5 billion in 2024 (up 23.3%) and was KRW 15.3 billion in 2025 (down 1.4%). Operating cash flow fell from KRW 14.3 billion in 2022 to KRW 5.06 billion in 2025, and the debt ratio rose from 64.5% in 2022 to 93.8% at the end of 2025.

Quarterly sales rose from KRW 48.9 billion in the third quarter of 2025 to KRW 56 billion in the second quarter of 2026, then fell to KRW 49.6 billion in the third quarter of 2026 (down 11.3% from the prior quarter).

Operating profit was KRW 2.08 billion, KRW 2.34 billion, KRW 3.14 billion and KRW 2.15 billion across the four quarters through the second quarter of 2026, and the third quarter of 2026 swung to an operating loss of KRW 3.06 billion.

The company said fixed costs and trial production costs from running the old and new plants side by side, along with costs of imported raw materials under a high exchange rate, pushed up the cost of sales ratio. R&D spending for the first nine months of 2026 was KRW 7.9 billion, up 24.8%, about 4.9% of sales.

Profit attributable to owners of the parent was KRW 2.61 billion, KRW 7.06 billion, KRW 3 billion, KRW 11.3 billion and a net loss of KRW 5.24 billion across the last five quarters, and the last four quarters total KRW 16.1 billion.

The gap between second-quarter operating profit of KRW 2.15 billion and owner profit of KRW 11.3 billion means non-operating items and tax effects should be checked in the quarterly filings.

05

Industry analysis

Quality standards for injectables and solid dosage forms are tightening toward global guidelines, which makes production infrastructure the starting point for competitiveness at companies targeting exports. Daehan Nupharm's new plant was reported to include an injectable line reflecting EU GMP Annex 1 guidelines.

The company said it is focusing this year's investment on global-standard production infrastructure aligned with PIC/S guidelines and on strengthening its new pipeline. On the cost side, a high exchange rate raised the cost of imported raw materials.

Overseas, the company is pursuing wellness injectables for vitamins, immunity, metabolic diseases and beauty, and has attended CPHI Worldwide. In therapeutics, obesity drug R&D is presented as a pillar for expanding its prescription drug portfolio.

Within KOSDAQ pharmaceuticals, the company is classified as a mid-sized player with prescription drugs, injectables and veterinary medicines. In terms of cycle position, it is in a transition phase after capacity investment, so fixed costs are recognized before utilization rises.

Sales have stayed near KRW 200 billion since 2022, so whether new capacity converts into revenue is a company-specific variable to watch.

06

Outlook

The company expects that once trial production at the new plant stabilizes and full-scale mass production is in place, the cost of sales ratio will improve and operating leverage will take effect.

As reported in May 2026, the new plant is under qualification review, and the injectable line is targeted to start in early 2027. A company official said the focus is on converting increased output and new products from 2027 into sales.

The new plant has injectable and solid dosage lines, reported to produce 800 million tablets and 200 million capsules a year. Total investment was about KRW 81 billion, well above the KRW 42.9 billion initially disclosed.

Overseas, the company is pushing export expansion centered on injectables for vitamins, immunity, metabolic diseases and beauty. On R&D, spending for the first nine months of 2026 rose to KRW 7.9 billion to strengthen the pipeline.

On finance, it repaid part of the borrowings used for the plant construction early, and the current ratio rose to 170.2% per company announcements. The next checkpoint is whether the injectable line starts in early 2027 and how the cost of sales ratio moves after it does.

07

Valuation

PER
4.4×
PBR
0.5×
ROE
11.8%
EPS
₩1,146
BPS
₩10,179
Dividend per share
₩100

Valuation can be read on two axes: earnings scale and net assets. Profit attributable to owners of the parent over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, totals KRW 16.1 billion, which is larger than the KRW 11.7 billion operating profit for 2025.

Whether non-operating items or tax effects lifted that figure needs to be checked. Full-year 2025 profit attributable to owners of the parent was KRW 15.3 billion, above operating profit.

At the end of 2025, total equity and owner equity were each KRW 139.9 billion, so the market capitalization relative to that base is the starting point for reading the price-to-book level.

Because quarterly results swing between profit and loss, multiples should be interpreted against the annual trend rather than a single quarter. Operating cash flow in 2025 was KRW 5.06 billion, down sharply from KRW 14.3 billion in 2022.

The debt ratio was 93.8% at the end of 2025, up from 64.5% in 2022, and the company reported 87.8% for the first nine months of 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Room for cost ratio improvement

The company said it expects cost ratio improvements once trial production at the new plant stabilizes and mass production is established. Fixed and trial production costs have been recognized first, so higher utilization could lower the cost burden relative to sales. Confirmation of the injectable line start in early 2027 would show whether this expectation is realized.

Rising product mix and overseas push

The product share of sales rose from 68.18% in 2022 to 76.05% in 2024. The company is pursuing overseas entry for wellness injectables in vitamins, immunity, metabolic diseases and beauty, and is widening customer contact through trade shows. A stronger product-based sales mix could support margin recovery even while top-line growth has been flat.

Steadier balance sheet

The company said it repaid part of the borrowings from plant construction early. Per its announcement, the current ratio rose 15.0 percentage points to 170.2%, and the debt ratio for the first nine months fell to 87.8% from a year earlier. Lower borrowing pressure can act as a cushion during the start-up phase, when fixed costs are high.

09

Bear factors

Swing to operating loss and fixed cost burden

The third quarter of 2026 swung to an operating loss of KRW 3.06 billion. The company attributed the higher cost of sales ratio to fixed costs, trial production expenses and imported raw material costs under a high exchange rate.

The 2025 operating margin of 5.8% was below 13.9% in 2022, so the pace of margin recovery remains a weakness until it is confirmed.

Flat sales and rising SG&A

Sales moved from KRW 198 billion in 2022 to KRW 202.4 billion in 2025, staying near KRW 200 billion. SG&A rose from KRW 63 billion in 2022 to KRW 78.2 billion in 2024. If expenses keep growing while sales stay flat, operating profit can continue to shrink.

Short-term borrowing and concentrated ownership

A 2025 report on the first half showed total borrowings of KRW 80.5 billion, of which about half, KRW 39.9 billion, was short-term. Cash and cash equivalents were KRW 16.1 billion in the same report. The largest shareholder's stake of 26.53%, as reported in 2025, also points to governance concentration.

10

Risk factors

Plant start-up and certification risk

The new plant is under qualification review, and the injectable line is targeted to start in early 2027. Delays in evaluation or product transfer would extend the period of fixed-cost burden. A later start would also push back the timing of any earnings recovery into 2027 and beyond.

Cost and exchange rate risk

The company said a high exchange rate raised the cost of imported raw materials. R&D spending for the first nine months of 2026 rose 24.8% to KRW 7.9 billion, adding weight to the cost base. If raw material costs and exchange rates stay unfavorable, the room for cost ratio improvement could be limited.

Financial capacity and earnings quality

The debt ratio was 93.8% at the end of 2025, and operating cash flow fell to KRW 5.06 billion in 2025. The KRW 16.1 billion in owner profit over the last four quarters has a wide gap against operating profit, so the contribution from core operations needs to be separated. If profits rely on non-operating items, quarterly volatility may remain high.

11

What to watch next

  1. Early 2027

    Whether the injectable line at the new plant starts. A delay would extend the fixed-cost burden into 2027 and beyond.

  2. End of March 2027

    Filing of the 2026 annual report. The key items are how the operating margin moved from 5.8% in 2025 and how the third-quarter operating loss is reflected in full-year figures.

  3. Around May 15, 2027

    The Q1 2027 quarterly report. Watch how the cost of sales ratio and operating profit compare with KRW 3.14 billion in the first quarter of 2026, and the change around the plant start.

  4. Around August 14, 2027

    The 2027 half-year report. The items to check are the cumulative cost ratio after the plant start, borrowing trends, and the contribution from overseas wellness injectables.

12

Overall view

Daehan Nupharm's sales have stayed near KRW 200 billion since 2022, while its operating margin fell from 13.9% to 5.8%. The third quarter of 2026 brought an operating loss of KRW 3.06 billion, which the company attributed mainly to new-plant fixed costs and R&D spending.

On the other side, a rising product mix, early repayment of borrowings and a lower debt ratio are positive changes on the financial side. However, the debt ratio of 93.8% at the end of 2025 and operating cash flow of KRW 5.06 billion in 2025 raise questions about financial capacity.

Owner profit of KRW 16.1 billion over the last four quarters has a wide gap against operating profit, so earnings quality should be separated quarter by quarter.

The next checkpoints are the injectable line start in early 2027, the full-year operating margin in the 2026 annual report, and the cost of sales ratio in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. medipharmhealth.co.kr
  2. comp.wisereport.co.kr
  3. dailypharm.com
  4. jasoseol.com
  5. newspim.com
  6. lawissue.co.kr
  7. specialtimes.co.kr
  8. medipana.com
  9. newspim.com
  10. pharmnews.com
  11. kr.investing.com
  12. medipharmhealth.co.kr
  13. m.news.nate.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis